TELA Bio (TELA) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

TELA TELA Bio

Watchlist

2.850
+0.050+1.79%

Close Dec 20 16:00 ET

2.850
0.0000.00%

Post 16:11 ET

112.26MMarket Cap-1.69P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswireDec 13 16:05 ET
Express News | TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ReutersDec 13 16:05 ET
The Past Five Years for TELA Bio (NASDAQ:TELA) Investors Has Not Been Profitable
Yahoo FinanceDec 1 07:27 ET
TELA Bio to Participate in Piper Sandler's 36th Annual Healthcare Conference
GlobeNewswireNov 19 16:05 ET
JMP Securities Maintains TELA Bio(TELA.US) With Buy Rating, Maintains Target Price $12
Moomoo NewsNov 13 01:32 ET · Ratings
TELA Bio, Inc. (TELA) Q3 2024 Earnings Call Transcript
Earnings Call TranscriptsNov 9 13:49 ET

Comments

Jaguar8

Oct 23 07:10

NEWS

$TELA Bio (TELA.US)$
TELA Bio Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
TELA Bio has announced the pricing of a public offering comprising 12,000,000 shares of common stock at $2.25 per share and pre-funded warrants for 5,800,000 shares at $2.2499 per warrant. The offering is expected to generate $40 million in gross proceeds before expenses. The company has granted underwriters a 30-day option to purchase up to 2,670,000 additional shares. The offering, exp...

Jaguar8

Apr 15 06:05

$TELA Bio (TELA.US)$
NEWS
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures
TELA Bio, Inc. announces the U.S. commercial launch of OviTex IHR, a reinforced tissue matrix for inguinal hernia repair. The product offers trocar-compatibility for laparoscopic and robotic procedures, with three configurations available. OviTex has a strong clinical track record with low recurrence rates and high pati...

stockhub

Mar 22 07:42

TELA

$TELA Bio (TELA.US)$
Beat revenue estimates and near miss on GAAP.
FDA approved surgical device
Buy this asap

Moomoo AI

Oct 9, 2023 19:45

Despite TELA Bio's high revenue growth, its P/S ratio barely aligns with industry median, indicating public skepticism about future growth. Its current stock price could be attractive, yet it shows two risk signs.